Our look is new. Our purpose is the same. Learn more about our brand evolution.
[…] of emails cross my desk every day, but one that came last September from an FSHD patient pulled me right down a rabbit hole that proved to be fantastic. It […]
[…] with a comprehensive diagnostics and treatment options for muscular dystrophies including Facioscapulohumeral Muscular Dystrophy ( FSHD). PanRARE connects patients, doctors, academia, key opinion leaders, drug discovery and development enterprises and […]
[…] one more time before ‘going public’ with it, or at least run it by an FSHD clinician who practices Western medicine. Today I can confidently say that I’ve met the […]
[…] the identification of compounds showing activity as a potential treatment to stop the progression of FSHD. This agreement marks the start of finding a drug to overcome FSHD. Facio’s drug […]
[…] the U.S. Food and Drug Administration (FDA) for the treatment of facioscapulohumeral muscular dystrophy ( FSHD). Resolaris, an investigational new drug representing aTyr’s first Physiocrine-based product candidate in the clinic, is […]
